Extra Heart Tissue Isolation During Pulsed Field Ablation for Persistent Atrial Fibrillation
Compares ablation strategies, with or without added posterior wall isolation, in persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.
Key facts
- Where
- Kunming, ChinaSee the site
Where in China
- Fuwai Yunnan HospitalKunming, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hangzhou Dinova EP Technology Co., Ltd
- Trial code
- NCT07590661
- Record updated
- 15 May 2026
- Original description
This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substrate, pulmonary vein isolation combined with superior vena cava isolation will be performed. For those with abnormal left atrial substrate, two strategies will be adopted: pulmonary vein isolation plus superior vena cava isolation, and pulmonary vein isolation combined with superior vena cava isolation and left atrial posterior wall isolation. Long-term follow-up will be conducted to observe the long-term clinical outcomes.Read full original descriptionShow less
Prospective, Multicenter, Randomized Controlled Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.
This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substrate, pulmonary vein isolation combined with superior vena cava isolation will be performed. For those with abnormal left atrial substrate, two strategies will be adopted: pulmonary vein isolation plus superior vena cava isolation, and pulmonary vein isolation combined with superior vena cava isolation and left atrial posterior wall isolation. Long-term follow-up will be conducted to observe the long-term clinical outcomes.
Inclusion: Older than 18 years; Diagnosed as persistent atrial fibrillation (AF); Definition: At least one episode of persistent AF was recorded on dynamic electrocardiogram (ECG) data within 12 months prior to enrollment, or other clinical evidence supporting persistent AF episodes lasting more than 7 days; Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.
Exclusion: Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 3 months prior to enrollment; Previous catheter ablation or surgical ablation for atrial fibrillation; History of prior left atrial appendage closure, patent foramen ovale closure, atrial septal defect closure, or repair surgery; Current or anticipated participation in other drug or device clinical trials; Atrial fibrillation is secondary to thyroid disease or other reversible factors; Rheumatic heart disease or the presence of moderate to severe mitral stenosis or regurgitation; Unstable angina; Contraindications to anticoagulation or history of coagulation disorders/abnormal bleeding; Active systemic infection; Life expectancy <12 months (e.g., advanced malignancy); Any other condition or abnormality deemed by the investigator to warrant exclusion; Left ventricular ejection fraction <40% or New York Heart Association (NYHA) class III/IV; Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² or history of renal dialysis; Evidence of left atrial or left atrial appendage thrombus on imaging examination; Left atrial anteroposterior diameter >55 mm; Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings; Presence of intracardiac thrombus, space-occupying lesions, or other abnormalities that preclude vascular access or catheter manipulation; Severe hepatic dysfunction; Pregnancy or breastfeeding.